The days of booming COVID-19 vaccine sales, which sent Moderna into the ranks of pharma's top companies, have passed. Now, the company is coping with low demand and taking inventory write-downs for “excess and obsolete” stock of its only marketed product.
Moderna’s third-quarter earnings report featured an array of financial losses and various charges.
privacy policy | terms of use | contact us | advertise | pharma jobs | pharma blogs | facebook | twitter
Copyright © 2025,